Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ECTRIMS 2022 | Biomarkers of disease activity and treatment response in MS

Mar Tintoré, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, and President of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), talks on identifying early clinical and radiological predictors of treatment response and disease activity. The increasing number of treatments available for remitting-relapsing multiple sclerosis (MS) requires the identification of early response predictors to treatments, both clinical and radiological. More controversial is how to use emerging biomarkers such as neurofilament light chain (NfL). Although NfL has shown positive results at a group level, its use at an individual level is still undefined. Additionally, NfL is associated with inflammatory activity, but once patients achieve no evidence of disease activity (NEDA), progression independent of relapses (PIRA) can still be present, and it is unclear whether NfL is the best marker when inflammation is not present. Perhaps imaging biomarkers, such as slowly expanding lesions, could play an important role in those settings. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


M Tintore has received compensation for:
Consulting services and speaking honoraria from Almirall, Bayer Schering Pharma, Biogen-Idec, Genzyme, Janssen, Merck-Serono, Novartis, Roche, Sanofi-Aventis, Viela Bio, Viatris and Teva Pharmaceuticals.
Receipt grants and research supports from Carlos III Health Institute, Foundation Genzyme, Foundation Salud 2000, Biogen-Idec, Novartis.